EMA Medicine safety communications
Tecentriq: adverse event
Published by European Medicines Agency: · Ref. EMEA/H/C/00414/II/0054
Summary
Adverse event
Medicine
Tecentriq
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): atezolizumab
- Therapeutic area: Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma
- ATC code: L01FX06
Measures and alternatives
- Regulatory outcome: Variation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗